RU2019118465A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019118465A3 RU2019118465A3 RU2019118465A RU2019118465A RU2019118465A3 RU 2019118465 A3 RU2019118465 A3 RU 2019118465A3 RU 2019118465 A RU2019118465 A RU 2019118465A RU 2019118465 A RU2019118465 A RU 2019118465A RU 2019118465 A3 RU2019118465 A3 RU 2019118465A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Addiction (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424378P | 2016-11-18 | 2016-11-18 | |
| US62/424,378 | 2016-11-18 | ||
| PCT/US2017/060964 WO2018093666A1 (en) | 2016-11-18 | 2017-11-09 | Compositions and methods for the treatment of opioid overdose |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019118465A RU2019118465A (ru) | 2020-12-18 |
| RU2019118465A3 true RU2019118465A3 (https=) | 2021-03-04 |
| RU2769397C2 RU2769397C2 (ru) | 2022-03-31 |
Family
ID=62146061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019118465A RU2769397C2 (ru) | 2016-11-18 | 2017-11-09 | Композиции и способы лечения передозировки опиоидами |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458091B2 (https=) |
| EP (1) | EP3541386A4 (https=) |
| JP (2) | JP7312698B2 (https=) |
| CN (1) | CN110139651A (https=) |
| AU (2) | AU2017360910B2 (https=) |
| CA (1) | CA3044221A1 (https=) |
| IL (2) | IL266674B2 (https=) |
| RU (1) | RU2769397C2 (https=) |
| WO (1) | WO2018093666A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
| WO2019157099A1 (en) | 2018-02-06 | 2019-08-15 | Aegis Therapeutics, Llc | Intranasal epinephrine formulations and methods for the treatment of disease |
| CA3100834A1 (en) * | 2018-05-17 | 2019-11-21 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| WO2019231993A1 (en) * | 2018-06-01 | 2019-12-05 | Purdue Pharma L.P. | Compositions and methods for opioid overdose rescue |
| EP3876938A4 (en) | 2018-11-06 | 2022-08-10 | Purdue Pharma L.P. | COMPOSITIONS AND METHODS OF ADMINISTRATION OF OPIOID ANTAGONISTS |
| CA3119031A1 (en) * | 2018-11-07 | 2020-05-14 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| EP3946547B1 (en) | 2019-03-26 | 2026-03-25 | Pinova Therapeutics Inc. | Devices and methods for delivering pharmaceutical compositions |
| US10653690B1 (en) * | 2019-07-09 | 2020-05-19 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| US10729687B1 (en) | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| WO2021159077A1 (en) * | 2020-02-07 | 2021-08-12 | Case Western Reserve University | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| US20230256099A1 (en) * | 2020-05-04 | 2023-08-17 | Amphastar Pharmaceuticals, Inc. | Safe Use of Bile Acids and Their Salts as Enhancers for Nasal Delivery of Pharmaceuticals |
| RS63725B1 (sr) | 2020-05-18 | 2022-12-30 | Orexo Ab | Nova farmaceutska kompozicija za davanje leka |
| US20220111162A1 (en) * | 2020-07-29 | 2022-04-14 | Lido Ventures Llc | Apparatus, system, and method for facilitating intranasal treatment of a patient |
| MX2023009055A (es) * | 2021-02-01 | 2024-01-05 | Clear Scient Inc | Compuestos de secuestro para el tratamiento de un trastorno por uso de sustancias y usos de los mismos. |
| US20220387407A1 (en) * | 2021-02-08 | 2022-12-08 | Case Western Reserve University | Compositions and methods for attenuating opioid induced cardio and/or respiratory depression |
| US11278709B1 (en) | 2021-03-12 | 2022-03-22 | Pocket Naloxone Corp. | Drug delivery device and methods for using same |
| AU2022323269A1 (en) * | 2021-08-04 | 2024-02-29 | Indivior Inc. | Compositions and methods for the treatment of opioid overdose |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| AR127780A1 (es) | 2021-11-25 | 2024-02-28 | Orexo Ab | Nueva composición farmacéutica que comprende adrenalina |
| JP2025521774A (ja) * | 2022-07-05 | 2025-07-10 | ジー２ジーバイオ インコーポレイテッド | セマグルチドまたはその薬学的に許容可能な塩を含む徐放性微粒球製剤およびその製造方法 |
| WO2024222920A1 (zh) * | 2023-04-28 | 2024-10-31 | 成都苑东生物制药股份有限公司 | 一种用于鼻内给药的药物制剂及其制备方法 |
| WO2025255416A1 (en) * | 2024-06-05 | 2025-12-11 | TMTRx, Inc. | Fentanyl and fentanyl analogue overdose reversal |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US4880813A (en) | 1988-07-22 | 1989-11-14 | Baker Cummins Pharmaceuticals, Inc. | Method of treatment for allergic rhinitis |
| US5069895A (en) | 1989-11-09 | 1991-12-03 | Diamond Ivan F | Methods for the treatment of alcohol intoxication and dependence |
| US5369095A (en) | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| IL97075A0 (en) | 1990-02-14 | 1992-03-29 | Alcon Lab Inc | Topical pharmaceutical composition containing an alkyl saccharide |
| US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
| RU2004107501A (ru) | 2001-08-14 | 2005-02-20 | Байотай Терапис Корпорейшн (Fi) | Способ лечения алкоголизма или злоупотребления алкоголем |
| US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
| US9114069B2 (en) | 2004-08-25 | 2015-08-25 | Aegis Therapeutics, Llc | Antibacterial compositions for drug administration |
| US8268791B2 (en) * | 2004-08-25 | 2012-09-18 | Aegis Therapeutics, Llc. | Alkylglycoside compositions for drug administration |
| US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
| WO2006025882A2 (en) | 2004-08-25 | 2006-03-09 | The Uab Research Foundation | Absorption enhancers for drug administration |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| CN1305474C (zh) * | 2004-10-13 | 2007-03-21 | 北京国药龙立生物医药新技术有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| US20070212307A1 (en) | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
| US20080090771A1 (en) | 2006-10-06 | 2008-04-17 | Shire Llc | Abuse-resistant hydrocodone compounds, compositions and methods of using the same |
| CA2677205A1 (en) | 2007-01-31 | 2008-08-07 | University Of Virginia Patent Foundation | Topiramate plus naltrexone for the treatment of addictive disorders |
| IL187159A0 (en) | 2007-07-03 | 2009-02-11 | Gur Megiddo | Use of metadoxine in relief of alcohol intoxication |
| WO2009029308A1 (en) | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| CA2756690C (en) | 2008-03-28 | 2016-08-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| AU2009236960A1 (en) | 2008-04-16 | 2009-10-22 | The Chemo-Sero-Therapeutic Research Institute | Method of producing thrombin-immobilized bioabsorbable sheet preparation |
| UA111342C2 (uk) | 2010-10-29 | 2016-04-25 | Троікаа Фармасьютікалс Лімітед | Назальні композиції вітаміну b12 |
| EP4085899A1 (en) | 2011-06-14 | 2022-11-09 | Neurelis, Inc. | Administration of benzodiazepine |
| US10485798B2 (en) | 2012-08-22 | 2019-11-26 | Aptapharma Inc. | Methylnaltrexone nasal formulations, methods of making, and use thereof |
| US20140171458A1 (en) | 2012-12-13 | 2014-06-19 | 3B Pharmaceuticals, Inc. | Intranasal naltrexone |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| WO2015054730A1 (en) | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| WO2015095389A1 (en) | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
| US9192570B2 (en) * | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| HK1231370A1 (zh) | 2014-03-14 | 2017-12-22 | 欧皮安特制药有限公司 | 鼻用药物产品及其使用方法 |
| US20160008277A1 (en) | 2014-07-09 | 2016-01-14 | Lightlake Therapeutics Inc. | Co-packaged drug products |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| KR102453781B1 (ko) * | 2016-06-24 | 2022-10-12 | 오피언트 파마슈티컬스, 인코퍼레이티드 | 알코올 사용 장애의 치료용 조성물, 장치 및 방법 |
| WO2018089709A1 (en) | 2016-11-09 | 2018-05-17 | Opiant Pharmaceuticals, Inc. | Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions |
| CN110139651A (zh) | 2016-11-18 | 2019-08-16 | 欧邦特制药公司 | 用于治疗阿片样物质过量的组合物和方法 |
| CN106361700A (zh) | 2016-11-25 | 2017-02-01 | 威海恒基伟业信息科技发展有限公司 | 盐酸纳美芬鼻腔给药制剂 |
| CA3100834A1 (en) | 2018-05-17 | 2019-11-21 | Aegis Therapeutics Llc | Formulations and methods for the prevention of opioid overdose |
| CA3119031A1 (en) | 2018-11-07 | 2020-05-14 | Opiant Pharmaceuticals, Inc. | Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose |
| US20200390691A1 (en) | 2018-12-20 | 2020-12-17 | Aegis Therapeutics, Inc. | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
| AU2019403368A1 (en) | 2018-12-20 | 2021-07-29 | Aegis Therapeutics, Llc | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |
-
2017
- 2017-11-09 CN CN201780081719.4A patent/CN110139651A/zh active Pending
- 2017-11-09 IL IL266674A patent/IL266674B2/en unknown
- 2017-11-09 IL IL312012A patent/IL312012A/en unknown
- 2017-11-09 JP JP2019526565A patent/JP7312698B2/ja active Active
- 2017-11-09 CA CA3044221A patent/CA3044221A1/en active Pending
- 2017-11-09 WO PCT/US2017/060964 patent/WO2018093666A1/en not_active Ceased
- 2017-11-09 US US16/461,354 patent/US11458091B2/en active Active
- 2017-11-09 RU RU2019118465A patent/RU2769397C2/ru active
- 2017-11-09 AU AU2017360910A patent/AU2017360910B2/en active Active
- 2017-11-09 EP EP17871739.3A patent/EP3541386A4/en active Pending
-
2022
- 2022-08-04 US US17/881,191 patent/US20220387306A1/en not_active Abandoned
-
2023
- 2023-07-10 JP JP2023112864A patent/JP7730443B2/ja active Active
-
2024
- 2024-02-19 AU AU2024201047A patent/AU2024201047A1/en active Pending
- 2024-06-25 US US18/753,188 patent/US20250127712A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL312012A (en) | 2024-06-01 |
| JP2023140359A (ja) | 2023-10-04 |
| AU2024201047A1 (en) | 2024-03-14 |
| IL266674B1 (en) | 2024-05-01 |
| US20220387306A1 (en) | 2022-12-08 |
| US11458091B2 (en) | 2022-10-04 |
| AU2017360910B2 (en) | 2023-11-23 |
| US20200060967A1 (en) | 2020-02-27 |
| US20250127712A1 (en) | 2025-04-24 |
| EP3541386A4 (en) | 2020-05-27 |
| RU2019118465A (ru) | 2020-12-18 |
| CA3044221A1 (en) | 2018-05-24 |
| EP3541386A1 (en) | 2019-09-25 |
| AU2017360910A1 (en) | 2019-05-30 |
| IL266674B2 (en) | 2024-09-01 |
| JP7730443B2 (ja) | 2025-08-28 |
| IL266674A (en) | 2019-07-31 |
| JP2019534315A (ja) | 2019-11-28 |
| CN110139651A (zh) | 2019-08-16 |
| WO2018093666A1 (en) | 2018-05-24 |
| JP7312698B2 (ja) | 2023-07-21 |
| RU2769397C2 (ru) | 2022-03-31 |